Literature DB >> 2465644

Flushing. Long-term side effect of orchiectomy in treatment of prostatic carcinoma.

C R Charig1, J S Rundle.   

Abstract

Orchiectomy is considered a safe and simple procedure, free from serious side effects, in the treatment of prostatic carcinoma. We have found that 76 percent of patients experienced postorchiectomy flushes, and 30 percent believed their symptoms warranted treatment. The flushing started at between one and twelve months (average 2.7 months) postoperatively and lasted an average of thirty months or, in some cases, up to the time of death (average 33 months). No single precipitating factor was found, and no single hormone seemed to be responsible. Special attention was given to the nonflushers to see whether or not it was of prognostic significance, and it appears that the slight elevation in the testosterone level sufficient to prevent flushing may indicate a nontesticular source of androgen. Medroxyprogesterone acetate (Provera), 5 mg twice daily, appeared to be an effective agent for controlling the flushes.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2465644     DOI: 10.1016/0090-4295(89)90385-3

Source DB:  PubMed          Journal:  Urology        ISSN: 0090-4295            Impact factor:   2.649


  15 in total

Review 1.  Periodic health examination, 1991 update: 3. Secondary prevention of prostate cancer. Canadian Task Force on the Periodic Health Examination.

Authors: 
Journal:  CMAJ       Date:  1991-09-01       Impact factor: 8.262

Review 2.  Mechanism of hot flashes.

Authors:  Santiago Vilar-González; Alberto Pérez-Rozos; Ruben Cabanillas-Farpón
Journal:  Clin Transl Oncol       Date:  2011-03       Impact factor: 3.405

3.  Survivorship, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology.

Authors:  Crystal S Denlinger; Tara Sanft; K Scott Baker; Shrujal Baxi; Gregory Broderick; Wendy Demark-Wahnefried; Debra L Friedman; Mindy Goldman; Melissa Hudson; Nazanin Khakpour; Allison King; Divya Koura; Elizabeth Kvale; Robin M Lally; Terry S Langbaum; Michelle Melisko; Jose G Montoya; Kathi Mooney; Javid J Moslehi; Tracey O'Connor; Linda Overholser; Electra D Paskett; Jeffrey Peppercorn; M Alma Rodriguez; Kathryn J Ruddy; Paula Silverman; Sophia Smith; Karen L Syrjala; Amye Tevaarwerk; Susan G Urba; Mark T Wakabayashi; Phyllis Zee; Deborah A Freedman-Cass; Nicole R McMillian
Journal:  J Natl Compr Canc Netw       Date:  2017-09       Impact factor: 11.908

Review 4.  Hot flashes: a review of pathophysiology and treatment modalities.

Authors:  Phuong Khanh H Morrow; Danielle N Mattair; Gabriel N Hortobagyi
Journal:  Oncologist       Date:  2011-10-31

5.  The importance of supportive care in optimizing treatment outcomes of patients with advanced prostate cancer.

Authors:  Florian Scotté
Journal:  Oncologist       Date:  2012

6.  Gabapentin for the management of hot flashes in prostate cancer survivors: a longitudinal continuation Study-NCCTG Trial N00CB.

Authors:  Amanda R Moraska; Pamela J Atherton; Daniel W Szydlo; Debra L Barton; Philip J Stella; Kendrith M Rowland; Paul L Schaefer; James Krook; James D Bearden; Charles L Loprinzi
Journal:  J Support Oncol       Date:  2010 May-Jun

7.  Acupuncture for hot flashes in patients with prostate cancer.

Authors:  Tomasz M Beer; Maria Benavides; Sandra L Emmons; Margaret Hayes; Guohui Liu; Mark Garzotto; Deirdre Donovan; Nina Katovic; Caron Reeder; Kristine Eilers
Journal:  Urology       Date:  2010-05-21       Impact factor: 2.649

8.  A phase III randomized, double-blind, placebo-controlled trial of gabapentin in the management of hot flashes in men (N00CB).

Authors:  C L Loprinzi; A C Dueck; B S Khoyratty; D L Barton; S Jafar; K M Rowland; P J Atherton; G W Marsa; W H Knutson; J D Bearden; L Kottschade; T R Fitch
Journal:  Ann Oncol       Date:  2009-01-06       Impact factor: 32.976

Review 9.  How long do the effects of acupuncture on hot flashes persist in cancer patients?

Authors:  Jessica W Frisk; Mats L Hammar; Martin Ingvar; Anna-Clara E Spetz Holm
Journal:  Support Care Cancer       Date:  2014-01-30       Impact factor: 3.603

10.  Randomized trial to assess the impact of venlafaxine and soy protein on hot flashes and quality of life in men with prostate cancer.

Authors:  Mara Z Vitolins; Leah Griffin; W Vic Tomlinson; Jacqueline Vuky; Paul T Adams; Dawn Moose; Bart Frizzell; Glenn J Lesser; Michelle Naughton; James E Radford; Edward G Shaw
Journal:  J Clin Oncol       Date:  2013-09-30       Impact factor: 44.544

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.